id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-3218-0006,FDA,FDA-2019-E-3218,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-01-17T05:00:00Z,2025,1,2025-01-17T05:00:00Z,,2025-01-17T15:05:27Z,,0,0,09000064868cb6f4
FDA-2019-E-3218-0005,FDA,FDA-2019-E-3218,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:03:25Z,,0,0,0900006486365a16
FDA-2019-E-3218-0004,FDA,FDA-2019-E-3218,Determination of Regulatory Review Period for Purposes of Patent Extension; VIZIMPRO,Notice,Determinations,2023-12-08T05:00:00Z,2023,12,2023-12-08T05:00:00Z,2024-02-07T04:59:59Z,2023-12-08T13:51:58Z,2023-27012,0,0,09000064863164a6
FDA-2019-E-3218-0003,FDA,FDA-2019-E-3218,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-12-02T05:00:00Z,2019,12,2019-12-02T05:00:00Z,,2019-12-02T18:11:18Z,,0,0,09000064841d955e
FDA-2019-E-3218-0001,FDA,FDA-2019-E-3218,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2019-07-02T04:00:00Z,2019,7,2019-07-02T04:00:00Z,,2019-07-02T19:34:00Z,,0,0,0900006483d59229
FDA-2019-E-3218-0002,FDA,FDA-2019-E-3218,"Patent Extension Application from Pfizer, Inc. (on behalf of Warner-Lambert Company LLC)",Other,Application,2019-07-02T04:00:00Z,2019,7,2019-07-02T04:00:00Z,,2019-07-02T19:37:15Z,,0,0,0900006483d5922a